GW-TT2 (intranasal nimodipine)

How it works

An intranasal reformulation of nimodipine (Gateway Biotechnology), an already-approved L-type calcium-channel blocker, designed to reach the brain and reduce neuronal excitability in recent-onset tinnitus. It targets excitability broadly rather than a specific circuit catalogued here. Preclinical/pre-IND, with first-in-human studies still being planned as of early 2026.

This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.